148 related articles for article (PubMed ID: 33622518)
21. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.
Marques P; Grossman A
Acta Med Port; 2015; 28(6):775-9. PubMed ID: 27265913
[TBL] [Abstract][Full Text] [Related]
22. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.
Atkins P; Ur E
Endocr Res; 2020 Nov; 45(4):246-253. PubMed ID: 32892666
[TBL] [Abstract][Full Text] [Related]
23. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
24. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
Guerrero E; Johnson DB; Bachelot A; Lebrun-Vignes B; Moslehi JJ; Salem JE
Eur J Cancer; 2019 May; 113():10-13. PubMed ID: 30954881
[No Abstract] [Full Text] [Related]
26. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
27. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab-Induced Secondary Hypophysitis.
Cheema A
Endocr Pract; 2018 Sep; 24(9):854. PubMed ID: 29624100
[No Abstract] [Full Text] [Related]
29. Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab-induced hypophysitis: early Australian experience.
De Sousa SM; Long GV; Tonks KT
Med J Aust; 2014 Aug; 201(4):198-9. PubMed ID: 25164840
[No Abstract] [Full Text] [Related]
31. Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis.
Ohnuma T; Matsuzawa T; Kinoshita M; Sano S; Kawamura T; Shimada S; Inozume T
J Dermatol; 2017 Nov; 44(11):1325-1326. PubMed ID: 27864834
[No Abstract] [Full Text] [Related]
32. Two cases of symptomatic secondary hypophysitis due to Rathke's cleft cysts treated with glucocorticoids: long-term follow-up.
Deguchi-Horiuchi H; Koide H; Sakuma I; Gao Y; Higuchi S; Nagano H; Hashimoto N; Horiguchi K; Iwadate Y; Inoshita N; Yokote K; Tanaka T
Endocr J; 2021 Mar; 68(3):269-279. PubMed ID: 33087628
[TBL] [Abstract][Full Text] [Related]
33. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
Dillard T; Yedinak CG; Alumkal J; Fleseriu M
Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
Chodakiewitz Y; Brown S; Boxerman JL; Brody JM; Rogg JM
Clin Neurol Neurosurg; 2014 Oct; 125():125-30. PubMed ID: 25127260
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab-related hypophysitis may precede severe CNS immune attack.
Köessler T; Olivier T; Fertani S; Marinari E; Dutoit V; Dietrich PY
Ann Oncol; 2016 Oct; 27(10):1975-6. PubMed ID: 27358386
[No Abstract] [Full Text] [Related]
36. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
[TBL] [Abstract][Full Text] [Related]
37. Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department.
Miller AH; Brock P; Jim Yeung SC
Ann Emerg Med; 2016 Aug; 68(2):249-50. PubMed ID: 27451306
[No Abstract] [Full Text] [Related]
38. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
[TBL] [Abstract][Full Text] [Related]
39. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
van der Hiel B; Blank CU; Haanen JB; Stokkel MP
Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
[TBL] [Abstract][Full Text] [Related]
40. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
